These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 22380736)
1. Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index. Liu G; Abraham S; Tran L; Vickers TD; Xu S; Hadd MJ; Quiambao S; Holladay MW; Hua H; Ford Pulido JM; Gunawardane RN; Davis MI; Eichelberger SR; Apuy JL; Gitnick D; Gardner MF; James J; Breider MA; Belli B; Armstrong RC; Treiber DK J Med Chem; 2012 Apr; 55(7):3250-60. PubMed ID: 22380736 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor. Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549 [TBL] [Abstract][Full Text] [Related]
3. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. Adams ND; Adams JL; Burgess JL; Chaudhari AM; Copeland RA; Donatelli CA; Drewry DH; Fisher KE; Hamajima T; Hardwicke MA; Huffman WF; Koretke-Brown KK; Lai ZV; McDonald OB; Nakamura H; Newlander KA; Oleykowski CA; Parrish CA; Patrick DR; Plant R; Sarpong MA; Sasaki K; Schmidt SJ; Silva DJ; Sutton D; Tang J; Thompson CS; Tummino PJ; Wang JC; Xiang H; Yang J; Dhanak D J Med Chem; 2010 May; 53(10):3973-4001. PubMed ID: 20420387 [TBL] [Abstract][Full Text] [Related]
4. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure. Kerekes AD; Esposite SJ; Doll RJ; Tagat JR; Yu T; Xiao Y; Zhang Y; Prelusky DB; Tevar S; Gray K; Terracina GA; Lee S; Jones J; Liu M; Basso AD; Smith EB J Med Chem; 2011 Jan; 54(1):201-10. PubMed ID: 21128646 [TBL] [Abstract][Full Text] [Related]
5. Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile. Chiang CC; Lin YH; Lin SF; Lai CL; Liu C; Wei WY; Yang SC; Wang RW; Teng LW; Chuang SH; Chang JM; Yuan TT; Lee YS; Chen P; Chi WK; Yang JY; Huang HJ; Liao CB; Huang JJ J Med Chem; 2010 Aug; 53(16):5929-41. PubMed ID: 20681538 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. Jung FH; Pasquet G; Lambert-van der Brempt C; Lohmann JJ; Warin N; Renaud F; Germain H; De Savi C; Roberts N; Johnson T; Dousson C; Hill GB; Mortlock AA; Heron N; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Green S; Brown E; Thompson K; Brightwell S J Med Chem; 2006 Feb; 49(3):955-70. PubMed ID: 16451062 [TBL] [Abstract][Full Text] [Related]
8. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase. Prime ME; Courtney SM; Brookfield FA; Marston RW; Walker V; Warne J; Boyd AE; Kairies NA; von der Saal W; Limberg A; Georges G; Engh RA; Goller B; Rueger P; Rueth M J Med Chem; 2011 Jan; 54(1):312-9. PubMed ID: 21128645 [TBL] [Abstract][Full Text] [Related]
9. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity. Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905). Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent and selective aurora kinase inhibitor. Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Rewcastle GW; Gamage SA; Flanagan JU; Frederick R; Denny WA; Baguley BC; Kestell P; Singh R; Kendall JD; Marshall ES; Lill CL; Lee WJ; Kolekar S; Buchanan CM; Jamieson SM; Shepherd PR J Med Chem; 2011 Oct; 54(20):7105-26. PubMed ID: 21882832 [TBL] [Abstract][Full Text] [Related]
13. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors. Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134 [TBL] [Abstract][Full Text] [Related]
14. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization. Pevarello P; Brasca MG; Orsini P; Traquandi G; Longo A; Nesi M; Orzi F; Piutti C; Sansonna P; Varasi M; Cameron A; Vulpetti A; Roletto F; Alzani R; Ciomei M; Albanese C; Pastori W; Marsiglio A; Pesenti E; Fiorentini F; Bischoff JR; Mercurio C J Med Chem; 2005 Apr; 48(8):2944-56. PubMed ID: 15828833 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675 [TBL] [Abstract][Full Text] [Related]
16. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783 [TBL] [Abstract][Full Text] [Related]
17. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509 [TBL] [Abstract][Full Text] [Related]
18. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors. Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284 [TBL] [Abstract][Full Text] [Related]
19. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives. Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I). Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]